Mary N K, Babu B H, Padikkala J
Amala Cancer Research Centre, Thrissur, Kerala, India.
Phytomedicine. 2003;10(6-7):474-82. doi: 10.1078/094471103322331412.
The antiatherogenic effect of a herbal formulation, Caps HT2, was evaluated as antioxidant, anticoagulant, platelet antiaggregatory, lipoprotein lipase releasing, anti-inflammatory and hypolipidaemic activity in rats. The formulation contained the methanolic extracts of selected parts of plants, Commiphora mukul, Allium sativum, Plumbago indica, Semecarpus anacardium, Hemidesmus indicus, Terminalia arjuna, Tinospora cordifolia, Withania somnifera and Ocimum sanctum. The formulation, Caps HT2 was found to scavenge superoxide and hydroxyl radicals; the IC50 required being 55.0 and 610.0 microg/ml respectively. The lipid peroxidation was found inhibited (50%) by 48.5 microg/ml of Caps HT2. The intravenous administration of the formulation (5 mg/kg) delayed the plasma recalcification time in rabbits and enhanced the release of lipoprotein lipase enzyme significantly (p < 0.001). The formulation also inhibited ADP induced platelet aggregation in vitro, which was comparable to commercial heparin. The anti-inflammatory action of the formulation was significant (p < 0.001) with acute and chronic inflammations induced by carrageenan and formalin respectively in rats. The hypolipidaemic effect of Caps HT2 was significant (p < 0.001) with the administration of the formulation, in diet-induced hyperlipidaemia of rats for a period of 30 days. Oral administration of the formulation, Caps HT2 (100, 200, 300 and 400 mg/kg) significantly raised HDL cholesterol levels. The atherogenic index and the reduction in body weight were significant indicating the effectiveness against hyperlipidaemia and obesity. All these results revealed the therapeutic potential of Caps HT2 against vascular intimal damage and atherogenesis leading to various types of cardiovascular problems.
一种草药制剂Caps HT2的抗动脉粥样硬化作用,通过其在大鼠体内的抗氧化、抗凝、抗血小板聚集、释放脂蛋白脂肪酶、抗炎和降血脂活性进行评估。该制剂含有植物没药、大蒜、白花丹、印度乌木、印度獐牙菜、印度楝、心叶地锦、印度人参和罗勒等选定部位的甲醇提取物。发现制剂Caps HT2能清除超氧阴离子和羟基自由基;清除超氧阴离子自由基的IC50为55.0微克/毫升,清除羟基自由基的IC50为610.0微克/毫升。发现48.5微克/毫升的Caps HT2可抑制脂质过氧化(50%)。静脉注射该制剂(5毫克/千克)可延长家兔血浆复钙时间,并显著增强脂蛋白脂肪酶的释放(p<0.001)。该制剂还能在体外抑制ADP诱导的血小板聚集,其效果与市售肝素相当。该制剂对大鼠角叉菜胶急性炎症和福尔马林慢性炎症均具有显著的抗炎作用(p<0.001)。给大鼠喂食高脂饲料30天诱导高脂血症,在此期间给予Caps HT2制剂,其降血脂作用显著(p<0.001)。口服Caps HT2制剂(100、200、300和400毫克/千克)可显著提高高密度脂蛋白胆固醇水平。动脉粥样硬化指数和体重减轻显著,表明其对高脂血症和肥胖症有效。所有这些结果揭示了Caps HT2对血管内膜损伤和动脉粥样硬化的治疗潜力,可预防各种类型的心血管问题。